Thank You for Visiting DIMA Biotech at BVS Tech Vendor Expo 2025!

Thank you for visiting the DIMA Biotech booth at the BVS Tech Vendor Expo 2025 in Boston on September 11. It was a great pleasure to meet you and exchange ideas on the latest research tools and solutions.
This event brought together numerous researchers and industry professionals, providing a valuable opportunity to exchange ideas on the latest scientific tools and solutions. We would like to thank all the visitors and partners who stopped by our booth—your support made this event truly rewarding.

DIMA Highlight

We’re excited to continue supporting your research through:

500+ in-stock Nanodisc membrane proteins

Currently, we offer over 500 in-stock Nanodisc products, covering more than 200 membrane protein targets, with a variety of tag options available (such as Flag, MBP, Strep, etc.) to meet diverse experimental needs. In addition to our catalog products, we also provide customized services, including biotin labeling, protein affinity binding analysis(SPR), and more, offering flexible support for your research workflows.

Our Nanodiscs provide a stable, native-like lipid bilayer environment for membrane proteins, making them ideal for applications such as membrane protein stabilization, structural biology(Cryo-EM), ligand screening, and antibody discovery.

Click to read our latest blog about Optimizing GPCR Expression and Purification.

Lead Monoclonal Antibodies for Antibody Drug Development

At present, DIMA has developed B cell seed libraries and the corresponding pilot antibody molecules for around 500+ targets for blood tumor, immune checkpoints and solid tumors. All targets have human-rabbit chimeric antibodies, and 50+ targets have completed humanization antibodies developed by our DiLibrary™ display platform.

ADC internalization & cytotoxicity evaluation

Including our MMAE IgG labeling reagent, we have developed a new solution—the Eribulin IgG Labeling Reagent. These solutions enable efficient assessment of ADC internalization and cytotoxic activity. Notably, our latest Eribulin IgG Labeling Reagent is now available for trial applications.